Company: NCEL
Filing Date: 2025-09-25
Form Type: F-1
Source: 0001213900-25-091697
Chunk: 26

Company: NewcelX Ltd.
Filing Date: 2025-09-25
Form: F-1
Chunk 26
---
                                            |     | We will not receive any proceeds from the sale of the Common Shares included in this prospectus by the Selling Shareholder. We may receive up to $25.0 million aggregate gross proceeds under the Purchase Agreement from sales of the Common Shares that we elect to make to the Selling Shareholder pursuant to the Purchase Agreement, if any, from time-to-time in our sole discretion, although the actual amount of proceeds that we may receive cannot be determined at this time and will depend on the number of Common Shares we sell under the Purchase Agreement and market prices at the times of such sales. In connection with the Purchase Agreement, we may request VWAP Purchases of the Total Commitment. Any proceeds that we receive from sales of our Common Shares to the Selling Shareholder or VWAP Purchases under the Purchase Agreement will be used for working capital and general corporate purposes. See “Use of Proceeds.” |
| Risk factors                                               |     | Investing in our securities involves a high degree of risk. You should read the “Risk Factors” section starting on page 13 of this prospectus, for a discussion of factors to consider carefully before deciding to invest in the Common Shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Nasdaq symbol:                                             |     | Our Common Shares are listed on Nasdaq under the symbol “NLSP”.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

| (1) | The number of the Common Shares                                                                                                       
 to be outstanding immediately after this offering as shown above assumes that all of the Common Shares offered hereby are sold and is 
 based on 4,252,025 Common Shares outstanding as of September 22, 2025. This number excludes:                                          |

| ● | 2,235,616 warrants to purchase 2,235,616 Common Shares issued as part of equity raises; |

| ● | 1,249,905 Preferred shares convertible into 1,249,905 Common Shares issued to accredited investors; |

| ● | 583,198 Preferred participation certificates convertible into 613,128 Common Shares issued to accredited investors; |

| ● | 930,787 Prefunded warrants convertible into 930,787 Common Shares issued to accredited investors; |

| ● | 32,002 Options convertible into 32,002 Common Shares; |

<div align='center'>12

RISK FACTORS</div>

Investing in our securities involves risks. Please carefully consider the risk factors described below and in our periodic reports filed with the SEC, including those set forth under the caption “